Fusion of biotechnology and medical technology.
Clinical studies and experience have shown that sustained anti-tumor effects are very limited. Cellular stress, triggered by chemotherapy, sooner or later leads to resistance in many cases. When treated with high doses, the tumor cell develops resistance mechanisms. These resistances enable the tumor cell to escape and continue to grow. Resistance to therapeutic antibodies and chemotherapy develop over time. Newly induced mutations, changed expression patterns and the upregulation of efflux pumps make current therapies ineffective.
A novel therapy option through the fusion of biotechnology and medical technology generates a locally limited therapy that enables efficient treatment at the target location over a long period of time. The principles of multifunctional antibody therapies are designed alongside one another without loss of avidity and in combination with other therapies.